Clinical Trials 2010 - Frankfurt

North West Business Group29 - 30 September 2010, Frankfurt, Germany.
In the current environment where minimising cost and delivering ROI are critical themes within the pharma industry, improving your clinical trial infrastructure can ensure that time is not wasted and you are maximising your investments. Attend Clinical trials 2010, this two day meeting which is concise and packed with value, Presentations that will be case-study oriented, supplemented by panel discussions and network with leading practitioners to provide information to keep clinical trials goal-oriented, on-time and cost-effective. Take-aways will include presentations with information that can readily be adapted to clinical trial projects in your organization.The 2010 event is set to be a highlight in the clinical trial events calendar. What's more, it is widely accepted that there is nothing better than to learn from the experience of experts rather than trying to build that knowledge yourself.

The programme covers a wide range of topics including:

  • Clinical Trials in the 21st Century
  • Clinical trials in emerging economies: myth and reality
  • How to optimize the global patient recruitment process
  • Working with Academic Study Groups
  • How to attract and retain clinical trials in western countries
  • Outsourcing Innovative approaches
  • The effect of EU regulations on conducting clinical trials

Joins some of the experts like:

  • Astrazeneca, Clinical Research Director Europe
  • Grunenthal, Head of Clinical Operations
  • MDC, Senior PartnerProduct Specialist Clinical Business Intelligence Systems
  • Novartis, Chief Scientific Officer
  • Glaxo Smith Kline, Director Clinical Research
  • Actelion, Director, Global Clinical Development Affairs
  • Novartis, Head Clinical Operations
  • Lundbeck, Senior Specialist, Outsourcing
  • Janssen-Cilag, Head Clinical Trials
  • Sanofi-Aventis, Head of Clinical Research Unit
  • Bayer Health care, EDC Director
  • Pfizer, Associate Director Worldwide Regulatory Affairs & Quality Assurance
  • And many more...

Who should attend?
This conference is designed to attract key decision makers from the Pharmaceutical industry: Presidents, Managing Directors, Country Managers, General Managers, Vice Presidents, Regional Directors/ Heads, Directors, Department Heads, Managers.

For further information and registration, please visit:
http://nwbg.eu/all-events/clinical-trials-2010/

Most Popular Now

Most popular vitamin and mineral supplements provi…

The most commonly consumed vitamin and mineral supplements provide no consistent health benefit or harm, suggests a new study led by researchers at St. Michael's Hospital...

AstraZeneca heads to 2018 ASCO Annual Meeting with…

AstraZeneca and MedImmune, its global biologics research and development arm, head to the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US...

Tiny particles could help fight brain cancer

Glioblastoma multiforme, a type of brain tumor, is one of the most difficult-to-treat cancers. Only a handful of drugs are approved to treat glioblastoma, and the median ...

New approach to immunotherapy leads to complete re…

A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was...

Amgen Foundation and Harvard team up to offer free…

The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspi...

The Pfizer Foundation announces $5 million in gran…

The Pfizer Foundation announced a new $5 million grant commitment to initiatives in low- and middle-income countries that provide family planning access and education for...

Study finds antioxidant-enriched vitamin reduces r…

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado School of Medicine have found that taking a specially formulated antioxid...

New drugs could also be deployed against lung and …

A new anti-cancer drug may be effective against a wider range of cancers than previously thought. Using a mouse model and samples taken from cancer patients, a team from ...

What would help or hinder patient participation in…

As clinical trials gear up with the aim of attaining the first FDA-approved treatments for mitochondrial disease, a new study reports for the first time what patients and...

Pfizer to expand venture investing with $600 milli…

Pfizer Inc. (NYSE:PFE) today announced it plans to invest $600 million in biotechnology and other emerging growth companies through Pfizer Ventures, the company’s venture...

Update on Phase III clinical trials of lanabecesta…

AstraZeneca and Eli Lilly and Company (Lilly) are discontinuing the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibi...

Soy lecithin NSAID combo drug protects against can…

When scientists at The University of Texas Health Science Center at Houston (UTHealth) applied a chemical found in soybeans to a non-steroidal anti-inflammatory drug (NSA...